LJI308 - An Overview
Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the initial-line therapy of CML-CP. 5 hundred and nineteen people with newly diagnosed CML-CP ended up randomly assigned to receive dasatinib at a dose of 100 mg the moment day-to-day (259 people) or imatinib at a dose of four hundred mg when day by